𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Towards the treatment of Alzheimer's disease: Discovery and development of novel subtype-specific M1 allosteric agonists

✍ Scribed by Lebois, Evan P.; Bridges, Thomas M.; Dawson, Eric S.; Kennedy, J. Phillip; Xiang, Zixiu; Jadhav, Satyawan B.; Yin, Huiyong; Meiler, Jens; Jones, Carrie K.; Conn, P. Jeffrey; Weaver, C. David; Lindsley, Craig W.

Book ID
123252006
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
41 KB
Volume
5
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Development of CDD-0102 as a selective M
Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease
✍ William S. Messer Jr.; Kenneth A. Bachmann; Colleen Dockery; Afif A. El-Assadi; πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 289 KB πŸ‘ 1 views

## Abstract Selective muscarinic agonists might be useful in the treatment of Alzheimer's disease. To help characterize the activity and functional selectivity of two M~1~ muscarinic agonists, secretion of amyloid precursor protein, brain penetration, side effect profiles, cognition‐enhancing prope

Development of M1 subtype selective musc
Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy
✍ R.D. Schwarz; M.J. Callahan; R.E. Davis; J.C. Jaen; H. Tecle πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

Clinical trials in Alzheimer's disease (AD) with first generation muscarinic agonists (e.g., arecoline, oxotremorine, pilocarpine) produced inconsistent results due to poor pharmacokinetic properties and a lack of separation between central and peripheral activities observed with these compounds. Se